Onconova Therapeutics (ONTX) Gets a Hold Rating from H.C. Wainwright


In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Onconova Therapeutics (ONTX). The company’s shares closed last Monday at $0.62.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 29.1% and a 47.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.

Onconova Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.10.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.93 and a one-year low of $0.19. Currently, Onconova Therapeutics has an average volume of 23.75M.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts